大中國(guó)區(qū)摘要
Region China Abstract

● 諾和諾德在整體胰島素市場(chǎng)的銷量市場(chǎng)份額達(dá)到48.5%。胰島素集中帶量采購(gòu)已于2022年5月實(shí)施，受其影響，大中國(guó)區(qū)胰島素銷售額以丹麥克朗計(jì)算下降16%。同時(shí)，由諾和佳^?和諾和益^?帶來(lái)的增長(zhǎng)，部分抵消了相關(guān)影響。

● Novo Nordisk has a volume market share of 48.5% of the total insulin market. Sales of insulin in Region China decreased by 16% measured in Danish kroner due to the implementation of Volume Based Procurement from May 2022. Meanwhile, the sales decline was partially countered by Ryzodeg^? and Xulthopy^?.

● 大中國(guó)區(qū)2型糖尿病治療領(lǐng)域GLP-1產(chǎn)品銷售以丹麥克朗計(jì)算增長(zhǎng)102%，反映出諾和泰^?的強(qiáng)勁增長(zhǎng)。諾和泰^?已被納入國(guó)家醫(yī)保目錄報(bào)銷體系。新版國(guó)家醫(yī)保藥品目錄已于2022年1月1日起正式實(shí)施。

● GLP-1 sales in Region China increased by 102% measured in Danish kroner. The sales growth reflects the uptake of Ozempic^?. Ozempic^? has been included on the National Reimbursement List in China. The new version of the National Reimbursement List in China has been implemented as of 1 January 2022.

● 大中國(guó)區(qū)罕見(jiàn)病領(lǐng)域銷售增長(zhǎng)101%。

● Rare disease sales in Region China increased by 101%.

財(cái)報(bào)摘要
Financial Report Abstract

● 經(jīng)營(yíng)利潤(rùn)以丹麥克朗計(jì)算增長(zhǎng)28%，以固定匯率（CER）計(jì)算增長(zhǎng)15%，至748億丹麥克朗。

● Operating profit increased by 28% in Danish kroner and by 15% at constant exchange rates (CER) to DKK 74.8 billion. 

● 北美運(yùn)營(yíng)部銷售以丹麥克朗計(jì)算增長(zhǎng)35%（以CER計(jì)算增長(zhǎng)21%），國(guó)際運(yùn)營(yíng)部銷售以丹麥克朗計(jì)算增長(zhǎng)17%（以CER計(jì)算增長(zhǎng)13%）。

● Sales in North America Operations increased by 35% in Danish kroner (21% at CER), and sales in International Operations increased by 17% in Danish kroner (13% at CER).

● 糖尿病和肥胖癥治療領(lǐng)域銷售以丹麥克朗計(jì)算增長(zhǎng)29%，至1564億丹麥克朗（以CER計(jì)算增長(zhǎng)19%），主要由GLP-1糖尿病治療領(lǐng)域銷售驅(qū)動(dòng)，其以丹麥克朗計(jì)算增長(zhǎng)56%（以CER計(jì)算增長(zhǎng)42%）。罕見(jiàn)病領(lǐng)域銷售以丹麥克朗計(jì)算增長(zhǎng)7%（以CER計(jì)算增長(zhǎng)1%）。

● Sales within Diabetes and Obesity care increased by 29% in Danish kroner to DKK 156.4 billion (19% at CER), mainly driven by GLP-1 diabetes sales growth of 56% in Danish kroner (42% at CER). Rare disease sales increased by 7% measured in Danish kroner (1% at CER).

● 肥胖癥治療領(lǐng)域銷售以丹麥克朗計(jì)算增長(zhǎng)101%（以CER計(jì)算增長(zhǎng)84%）。2022年12月，Wegovy^?在美國(guó)市場(chǎng)的供貨已再次獲得保證。

● Obesity care sales grew by 101% in Danish Kroner (84% at CER). All Wegovy^? dose strengths were made available again in the US in December 2022.

● 在研發(fā)領(lǐng)域，諾和諾德在NASH領(lǐng)域啟動(dòng)了兩項(xiàng)基于siRNA技術(shù)平臺(tái)的1期臨床試驗(yàn)。

● Within R&D, Novo Nordisk initiated two phase 1 trials in NASH based on the siRNA technology platform.

● 展望2023年，以 CER 計(jì)算的銷售和經(jīng)營(yíng)利潤(rùn)增長(zhǎng)目前均預(yù)計(jì)為13-19%。以丹麥克朗報(bào)告的銷售和經(jīng)營(yíng)利潤(rùn)增長(zhǎng)目前預(yù)計(jì)將比以 CER 計(jì)算的增長(zhǎng)率低分別4個(gè)和5個(gè)百分點(diǎn)。

● For the 2023 outlook, both sales and operating profit growth are expected to be 13-19% at CER. Sales and operating profit growth reported in Danish kroner are expected to be 4 and 5 percentage points lower than at CER, respectively. 

● 在將于2023年3月23日舉行的年度股東大會(huì)上，董事會(huì)將提議在2022年期末每股派息8.15丹麥克朗。預(yù)計(jì)2022年的總股息將為每股12.40丹麥克朗，其中每股4.25丹麥克朗的股息已于2022年8月作為中期股息予以派發(fā)。董事會(huì)還決定啟動(dòng)一項(xiàng)為期12個(gè)月，最多280億丹麥克朗的新股票回購(gòu)計(jì)劃。

● At the Annual General Meeting on 23 March 2023, the Board of Directors will propose a final dividend of DKK 8.15 for 2022 per share. The expected total dividend for 2022 is DKK 12.40 per share, of which DKK 4.25 was paid as interim dividend in August 2022. The Board of Directors has decided to initiate a new 12-month share repurchase programme of up to DKK 28 billion.

諾和諾德全球總裁兼CEO周賦德（Lars Fruergaard J?rgensen）表示：“我們對(duì)2022年實(shí)現(xiàn)雙位數(shù)銷售增長(zhǎng)感到非常滿意。增長(zhǎng)由用于糖尿病和肥胖癥治療的創(chuàng)新GLP-1類藥物所驅(qū)動(dòng)。超過(guò)3600萬(wàn)糖尿病患者從我們的治療產(chǎn)品中獲益。我們的戰(zhàn)略愿景持續(xù)取得進(jìn)展，在2023年，我們將繼續(xù)專注于強(qiáng)大的業(yè)務(wù)運(yùn)營(yíng)，擴(kuò)充并推進(jìn)公司創(chuàng)新產(chǎn)品管線，并為擴(kuò)大現(xiàn)有和未來(lái)的產(chǎn)品組合的產(chǎn)能進(jìn)行重點(diǎn)投資。”

Lars Fruergaard J?rgensen, president and CEO: "We are very pleased with the double-digit sales growth in 2022 driven by our innovative GLP-1-based diabetes and obesity treatments, and more than 36 million people living with diabetes are now benefiting from our treatments. We continued to make progress on our Strategic aspirations and in 2023, we will continue our focus on strong commercial execution, expanding and progressing our innovative pipeline and investing significantly in the expansion of production capacity for current and future portfolio."